NKGen Biotech

NKGen Biotech EPS Growth

The EPS Growth of NKGen Biotech (NKGN) as of Nov 22, 2026 is 59.47 %. In the previous year, EPS Growth was -203.87 % — a change of -129.17% (higher).

EPS Growth

59.47 %

YoY

-129.17%

Last updated:

EPS Growth of NKGen Biotech is 2025 59.47 % . EPS Growth of NKGen Biotech was 2024 -203.87 % . It decreases by -129.17% higher compared to the previous year.

The NKGen Biotech EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2022
-15.00 USD
Jan 1, 2023
-203.87 USD
Jan 1, 2025
59.47 USD
The NKGen Biotech EPS Growth history
YEAREPS GrowthYoY
59.47 %-129.17%
-203.87 %+1,259.43%
-15.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

EPS Growth of NKGen Biotech is 59.47 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's NKGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — NKGen Biotech

All Key Metrics — NKGen Biotech